Premium
An account of the quality of life of patients after treatment for non‐functioning pituitary tumours
Author(s) -
Page Renee C. L.,
Hammersley Margaret S.,
Burke Chris W.,
Wass John A. H.
Publication year - 1997
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1046/j.1365-2265.1997.1400957.x
Subject(s) - medicine , pituitary disease , quality of life (healthcare) , hypopituitarism , igfbp3 , pituitary gland , anterior pituitary , hormone , radiation therapy , pituitary tumors , endocrinology , growth hormone deficiency , growth hormone , receptor , nursing , growth factor
OBJECTIVE Studies assessing quality of life in GH‐deficient adults have shown varying results. This may be due to a number of factors including varying causes of GH deficiency, the use of radiotherapy in treatment and patient selection. We aimed to assess whether anterior pituitary hormone deficiency or external pituitary radiotherapy influenced the quality of life of patients with non‐functioning pituitary tumours. PATIENTS We studied 48 patients treated and under follow up for non‐functioning pituitary tumours on standard hormone replacement therapy excluding GH. There were 21 females and 27 males with a mean age of 59±12 years. We also studied 42 control patients who had undergone mastoid surgery and were followed at least annually. There were 17 females and 25 males with a mean age of 61±14 years. DESIGN All patients attended a research clinic and completed the Short Form 36 (SF36) and General Well Being Schedule (GWBS) to assess quality of life. Thyroid function tests, IGF1 and IGFBP3 were measured on all patients. Gonadotrophin and cortisol measurements were made on the patients with pituitary disease where appropriate. RESULTS IGF1 and IGFBP3 levels were lower in the pituitary patients compared with controls: 104±98 vs 143±37 μg/l ( P <0.0001) and 2.9±0.75 vs 3.3±0.52 mg/l ( P <0.004). There were no significant differences in the quality of life scores between the pituitary patients and the control subjects. There was also no difference in quality of life between pituitary patients with two or more hormone deficiencies ( n =29) compared with controls. Patients who had received radiotherapy ( n =18), when compared with controls, had a decreased mental health score using the SF36 71±21 vs 81±17 ( P <0.05) and decreased total GWBS score 70±20 vs 82±17 ( P <0.05). Subscore analysis of GWBS showed this to be due to depression and decreased control of emotions. CONCLUSIONS We found that the quality of life of patients treated and under follow up for non‐functioning pituitary tumours was similar to that of patients treated by mastoid surgery and under similar follow up. The pituitary patients deficient in two hormones and thus most likely to be GH deficient were also similar to the controls. These results suggest that adding GH replacement in this patient group may not be routinely indicated for improvement in quality of life and needs careful assessment. Patients who had received radiotherapy were more depressed and anxious than controls. Further investigation into the psychological and psychomotor effects of radiotherapy in this group of patients is required.